טוען...
Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine
The RV3-BB human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth. A phase IIa safety and immunogenicity trial was undertaken in Dunedin, New Zealand between January 2012 and April 2014. Healthy, full-term (≥ 36 weeks gestation) babies, who were 0–5 d ol...
שמור ב:
| הוצא לאור ב: | Hum Vaccin Immunother |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5975418/ https://ncbi.nlm.nih.gov/pubmed/28481726 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2017.1323591 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|